The DOI matches its Crossref record; 111 of the 113 references it cites were found in a registry or an index.
Ageing and multiple sclerosis
Open accessAbstract
The factor that is most relevant and strongly associated with the clinical course of multiple sclerosis is chronological age. Very young patients exclusively have relapsing remitting disease, whereas those with later onset disease face a more rapid development of permanent disability. For people with progressive multiple sclerosis, the poor response to current disease modifying therapies might be related to ageing in the immune system and CNS. Ageing is also associated with increased risks of side-effects caused by some multiple sclerosis therapies. Both somatic and reproductive ageing processes might contribute to development of progressive multiple sclerosis. Understanding the role of ageing in immune and neural cell function in patients with multiple sclerosis might be key to halting non-relapse-related progression. The growing literature on potential therapies that target senescent cells and ageing processes might provide effective strategies for remyelination and neuroprotection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of remyelination has been shown to depend on multiple factors such as, age, disease duration and lesion location.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [7]
Citations
Cites
DNA methylation-based biomarkers and the epigenetic clock theory of ageing
Horvath, S., & Raj, K. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0004-3 · Cited by 3,095
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
The ageing systemic milieu negatively regulates neurogenesis and cognitive function
Villeda, S. A., Luo, J., Mosher, K. I., Zou, B., Britschgi, M., Bieri, G., Stan, T. M., Fainberg, N., Ding, Z., Eggel, A., et al. (2011) · Nature · doi:10.1038/nature10357 · Cited by 1,763
Blackburn, E. H., Epel, E. S., & Lin, J. (2015) · Science · doi:10.1126/science.aab3389 · Cited by 1,596
Magliozzi, R., Howell, O. W., Vora, A., Serafini, B., Nicholas, R. S., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,486
Microglial control of astrocytes in response to microbial metabolites
Rothhammer, V., Borucki, D. M., Tjon, E. C., Takenaka, M. C., Chao, C.-C., Ardura-Fabregat, A., de Lima, K. A., Gutiérrez-Vázquez, C., Hewson, P., Staszewski, O., et al. (2018) · Nature · doi:10.1038/s41586-018-0119-x · Cited by 1,051
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine
Haghikia, A., Jörg, S., Duscha, A., Berg, J., Manzel, A., Waschbisch, A., Hammer, A., Lee, D.-H., May, C., Wilck, N., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.007 · Cited by 927
Review: microglia of the aged brain: primed to be activated and resistant to regulation
Norden, D. M., & Godbout, J. P. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2012.01306.x · Cited by 792
A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis
Absinta, M., Maric, D., Gharagozloo, M., Garton, T., Smith, M. D., Jin, J., Fitzgerald, K. C., Song, A., Liu, P., Lin, J.-P., et al. (2021) · Nature · doi:10.1038/s41586-021-03892-7 · Cited by 768
Self-citation
Research works printed but not linked: 3
- Guan, 2015, Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening, Mol Cell Biochem, 400, 183, 10.1007/s11010-014-2274-1 · DOI · Paper page
- Maggi, 2021, Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis, Neurology, 97, e543, 10.1212/WNL.0000000000012326 · DOI
- Wolinsky, 2018, Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the phase 3 ORATORIO study, Int J MS Care, 20, 32
Cited by
Sorted by citations
Items 201–260 of 260
Oligodendrocyte progenitor cell responses to inflammatory demyelination with agingPreprint
Fresenko, E. E., Bahri, C. N., Ahmed, N. F., Packer, D., Tabor, B. J., Sun, W., Wedemeyer, M. A., & Harrington, C. A. (2025) · Research Square · doi:10.21203/rs.3.rs-7614774/v1
Fresenko, E. E., Bahri, C. N., Burson, B. J., Ahmed, N. F., Packer, D., Tabor, B. J., Beirowski, B., Sun, W., Wedemeyer, M. A., & Harrington, C. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.22.677854
Reinsberg, H., Oertel, F. C., Casillas, D. I., Kaufhold, G. N., Montes, S. C., Bereuter, C., Chapman, M. C., Sperber, P. S., Cree, B., Bellmann–Strobl, J., et al. (2025) · Multiple Sclerosis Journal · doi:10.1177/13524585251374507
Development and Usability of MSafe: A Fall Risk Application for Older Adults with Multiple Sclerosis
Hsieh, K. L., Backus, D. A., Willingham, T. B., & Sanford, J. A. (2025) · Sensors · doi:10.3390/s25227075
Arelis, A. A., Barajas, B. V. R., Gómez, A. M. C., Yepez, J. E., Saldaña-Cruz, A. M., & Fragoso-Ruiz, A. (2025) · Brain Sciences · doi:10.3390/brainsci15121251
Sato, S., Uwatoko, H., Yaguchi, H., Yamada, M., Sato, K., Kawashima, A., Fukazawa, T., & Yabe, I. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6217-25
Zhang, Y., ZHU, Z., Li, Z., Feng, J., Long, J., Deng, Y., Ahmed, W., Khan, A. A., Huang, S., Fu, Q., et al. (2024) · Figshare · doi:10.6084/m9.figshare.27132726
Sundvall, L., Mikkelsen, I. K., Hansen, B., Eskildsen, S. F., Hjørringgaard, M. M., Nygaard, M. K. E., Rasmussen, P. V., Petersen, T., & Østergaard, L. (2025) · Neuroimage Reports · doi:10.1016/j.ynirp.2025.100309 · Cited by 1
How to manage an elderly patient with multiple sclerosis?
Chojdak-Łukasiewicz, J. (2025) · Aktualności Neurologiczne · doi:10.15557/an.2025.0021
Impact of multiple sclerosis on life expectancy: a review
Lyutov, O. V., Kutlubaev, M. A., Kuzmina, U. S., Фанильевна, А. Н., Saitova, Y. A., & Bakhtiyarova, K. Z. (2025) · Neurology Bulletin · doi:10.17816/nb646588
Neuronal TrkB supports adult cortical oligodendrogenesis in the brains of older adult mice
Nicholson, M., Wood, R. J., Murray, S. S., & Fletcher, J. L. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.12.009
Pu, Y., Feng, J., Meng, H., Xiao, H., Li, X., Jin, Z., Lu, W., Xi, X., Wu, T., Yuan, B., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78146
Treatment strategies for multiple sclerosis in middle-aged and older adults
Merzhuk, V. O., Shulga, O. D., Skrypka, M. P., Klochak, A. V., & Potapovych, J. O. (2025) · Psychiatry Neurology and Medical Psychology · doi:10.26565/2312-5675-2025-32-09
Evanchick, C., Lopez, N., Gromisch, E. S., Campo, M. A., & DelMastro, H. M. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107067
Involvement of microglial aging in neurodegenerative diseases: a focus on multiple sclerosis
Theotokis, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27340-7.00005-x
Simonsen, C. S., König, M. S. S., Bjelland, S. H., Andersen, H.-M., Dugstad, T., & Torkildsen, Ø. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-00909-z
Menopause is a physiological progression event for women with multiple sclerosis: Commentary
Graves, J. S. (2026) · Multiple Sclerosis Journal · doi:10.1177/13524585261429811
Self-citationKhabazian, T., Khabazian, A., Saleh, M. H. A., SamavatiJame, F., Mohammadi, S., & Koopaie, M. (2026) · BMC Oral Health · doi:10.1186/s12903-026-08280-z
Wang, Z. X., Han, D., Qiao, X., Zhao, X., Zhao, C., Liu, S., Tao, R., Jin, M., & Qu, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1740656
P2X4 Drives Sex-Specific neuroprotection in autoimmune neuroinflammation
Mata, P., Bosch-Juan, M., Luengo-Arias, S., Montilla, A., Astiz, M., Battefeld, A., Carracedo, S., Sánchez‐Gómez, M. V., Matute, C., Pérez‐Samartín, A., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106771 · Cited by 1
Tang, L., Huang, J., Xia, R., Xu, W., Li, J., & Zhang, M. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106164
Real-world outcomes of cladribine in people ≥55 years of age with multiple sclerosis
Smoot, K. E., Stuchiner, T. L., Gervasi-Follmar, T., & Chen, C. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107215
Orme, D. R., Matesen, E., Conway, D. S., Thompson, N., & Hua, L. H. (2026) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/20552173261448005
Self-citationNervous System Disorders and Disability
Malviya, R., & Rajput, S. (2026) · SpringerBriefs in modern perspectives on disability research. · doi:10.1007/978-981-95-9223-4_3
A CSF disease-associated macrophage signature defines progressive multiple sclerosis
Börsch, A., Riethues, F., Schulte‐Mecklenbeck, A., Wang, X., Heming, M., Lu, I., Müller‐Miny, L., Wiendl, H., Groß, C. C., Bernard‐Valnet, R., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03861-9
Monaghan, P. G., Johnson, K. A., Bove, R. M., Fling, B. W., & Fritz, N. E. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2676826
Microenvironmental Regulation of Central Nervous System Myelination and Remyelination
Wang, Y., Tan, L., Lao, L., Huang, X., Zhang, S., & Sun, H. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin43257
Distinct age-related pattern of mitochondrial somatic mutations across multiple sclerosis phenotypes
Esposito, F., Misra, K., Doyle, F., Clarelli, F., Simone, A. D., Giordano, A., Visentin, G., Mascia, E., Rocca, M. A., Filippi, M., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13926-7
Reuter, E., Luerweg, J., Katsimpoura, M., Haselon, J., Bratek, D., Assfoor, Z., Schuetrumpf, C., Klimas, R., Jessen, J., Carsten Saft, C., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13906-x
Menopause and ageing in women with multiple sclerosis
Simonsen, C. S., & Celius, E. G. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1838550
Aged oligodendrocyte progenitors retain the capacity to respond to an inflammatory insult
Fresenko, E. E., Kaiser, K. E., Burson, B., Bahri, C. N., Ahmed, N., Bozik, J. B., Packer, D., Tabor, B. J., Beirowski, B., Wedemeyer, M. A., et al. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115874
Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers
Pawlitzki, M., Kirschner, P., Masanneck, L., Hagler, R., Meier, E., Vach, M., Inojosa, H., Ziemssen, T., Ivan, V. L., More, S., et al. (2026) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864261458516
Basheikh, M., & Badahdah, A. A. (2025) · International Journal of Health & Allied Sciences · doi:10.4103/ijhas.ijhas_20_25
DIscontinuation of disease-modifying therapies in older adults with multiple sclerosis
Li, J., Hutton, G. J., & Aparasu, R. R. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107378
Tailoring disease-modifying therapy approaches across multiple sclerosis sub-populations
Aboseif, A., Zeydan, B., Nathoo, N., Kantarci, O. H., Amezcua, L., Voskuhl, R. R., Bove, R. M., Hua, L. H., Ontaneda, D., Conway, D. S., et al. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107389
Self-citationInojosa, H., Masanneck, L., Akgün, K., Hagler, R., Meuth, S. G., Otto, C., Schindler, P., Schulze-Bosse, K., Kühle, J., Benkert, P., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-13986-9
Preventing frailty in multiple sclerosis is a realistic goal: No
Scalfari, A., & Bianchi, A. (2026) · Multiple Sclerosis Journal · doi:10.1177/13524585261466107
Mao, S., & Wu, L. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1862602
Lesion-specific circular RNA and mRNA signatures in secondary progressive multiple sclerosis
Gao, Y., Takenaka, K., Santucci, K., Lindner, G., Cheng, Y., Xu, S.-M., & Janitz, M. (2026) · Molecular Brain · doi:10.1186/s13041-026-01333-y
Ghoumari, A. M., & Schumacher, M. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107545
Roeder, H. J., & Leira, E. C. C. (2026) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-026-01506-1
Bae, M., Pollak, C., & Blumen, H. M. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107405
Otto, F., Kliushnikova, D., Radlberger, R. F., Yasaroglu, S., Moser, T., Harrer, A., Kratzer, K., Hitzl, W., Gradl, C., Schmidauer, M., et al. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70483
Ghazy, H. E., Ali, Z. H., & Medhat, T. (2026) · Scientific Reports · doi:10.1038/s41598-026-63991-1
Shared etiology of late- and adult-onset multiple sclerosis
Karrenbauer, V. D., Olsson, T. P., Alfredsson, L. S., & Hedström, A. K. (2026) · Multiple Sclerosis Journal · doi:10.1177/13524585261472320
Moukhine, A., Rollot, F., Casey, R., Collongues, N., Vukusic, S., Mathey, G., Dubessy, A., Ciron, J., Seze, J. D., Ruet, A., et al. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70497
Impact of frailty on multiple sclerosis
Wicks, T. R., Bergsland, N., Zivadinov, R., Weinstock‐Guttman, B., & Ramanathan, M. (2026) · Multiple Sclerosis Journal · doi:10.1177/13524585261475090
Sex- and age-specific associations of VEGFA polymorphisms with multiple sclerosis susceptibility
Kaikarytė, K., Rubėnė, S., Vilkevičiūtė, A., Balnytė, R., Ulozienė, I., & Liutkevičienė, R. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2715843
Cai, Y., Bao, Y., Li, Y., Gu, J., Ran, Q., Zhou, Y., Dong, L., Wang, D., Zhao, X., Cheng, Y., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1805464
Immunogenic cell death in CNS diseases: From bench to bedside
Li, P., Zhou, Z., Qing, Y., Wei, X., Mei, Z., & Zhang, W. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103342
Baghbanian, S. M., Bakhshi, A., Charati, J. Y., Alaee, A., & Hoseinimayvan, N. (2026) · Neurological Research · doi:10.1080/01616412.2026.2730590
Li, Y.-J., Jiang, W., Zhang, C., Rommer, P. S., Levy, M., Paul, F., & Shi, F. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01863-x
Freedman, D., Oh, J., & Feinstein, A. (2026) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20260024
Cognitive Projection of Upper Cervical Spinal Cord Cross‐Sectional Area in Multiple Sclerosis
Çınar, B. P., Alıcıoğlu, B., İyilikci, O., Açıkgöz, M., Yüksel, B., Ethemoğlu, Ö., Bülbül, N. G., Boz, B. D., Ceylan, N., Uçar, A. T., et al. (2026) · Acta Neurologica Scandinavica · doi:10.1155/ane/1697161
Nicolella, V., Polito, C., Criscuolo, V., Varelli, M., Fasano, S., Fiorenza, M., Pascarella, G., Carotenuto, A., Maria, P., Lanzillo, R., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14157-6
Amin, M., Palmer, K. N., Samara, A., & Cohen, J. A. (2026) · Drugs · doi:10.1007/s40265-026-02391-1
Sato, S. D., Richmond, S. B., Fling, B. W., & Seidler, R. D. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107958
Cellular senescence in multiple sclerosis: hallmarks, immunosenescence, and therapeutic implications
Yousef, A., Seubert, J. M., Power, C., & Nathoo, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1944657
Infection Risk During Rituximab Therapy in Multiple Sclerosis
Pihl-Jensen, G., Selle, M. L., Aarseth, J. H., Myhr, K., Torkildsen, Ø., Nakken, O., & Holmøy, T. (2026) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200664
Gommerman, J. L., Akassoglou, K., Baranzini, S. E., Becher, B., Brilot, F., Castelo‐Branco, G., Dunn, S. E., Faiz, M., Flügel, A., Ghasemlou, N., et al. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01272-1
Self-citation
Metadata
- Authors
- Graves, J. S., Krysko, K. M., Hua, L. H., Absinta, M., Franklin, R. J. M., & Segal, B. M.
- Affiliations
- United States Department of Veterans Affairs (US)
- St. Michael's Hospital (CA)
- Cleveland Clinic (US)
- Johns Hopkins University (US)
- Wellcome/MRC Cambridge Stem Cell Institute (GB)
- The Ohio State University (US)
- Corresponding author
- Graves, Jennifer S
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 22
- Issue
- 1
- Pages
- 66-77
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W4303473149
- Cited by
- 260
- References
- 113
- Citations by year
- 2026: 74 · 2025: 84 · 2024: 68 · 2023: 33
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 162 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet Neurology (acceptedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- National Institute of Neurological Disorders and Stroke
- Multiple Sclerosis Society (MS50)
- Conrad N. Hilton Foundation (17313)
- Fondazione Cariplo (1677)
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Fondazione per la Ricerca Biomedica (1750327)
- Ohio State University
- Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge (203151/Z/16/Z)
- Wellcome Trust
- National Eye Institute
- National Institutes of Health (R01EY028350, R01EY029159, R01NS105385)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, aging, age of onset, relapsing-remitting multiple sclerosis, progressive multiple sclerosis, disability progression, immunosenescence, disease-modifying therapy, adverse drug reactions, reproductive aging, cellular senescence, senolytics, remyelination, neuroprotection
- MeSH terms
- Aging, Disabled Persons, Persons with Disabilities, Humans, Multiple Sclerosis, Disease Progression, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
